| ADaM |
Analysis Data Model; a CDISC standard for deriving analysis-ready datasets from SDTM tabulations |
| AE |
Adverse Event; any untoward medical occurrence in a trial participant, whether or not related to the investigational product |
| AI |
Artificial Intelligence; computational systems that perform tasks typically requiring human intelligence, such as pattern recognition or decision support |
| ALCOA |
Attributable, Legible, Contemporaneous, Original, and Accurate; the five principles governing data integrity in clinical trials |
| ANDA |
Abbreviated New Drug Application; a regulatory submission to FDA for approval of a generic drug product, referencing the innovator’s safety and efficacy data |
| API |
Application Programming Interface; a set of protocols enabling software systems to communicate and exchange data |
| BIMO |
Bioresearch Monitoring; the FDA program that conducts inspections of clinical investigators, sponsors, IRBs, and contract laboratories to verify data integrity and regulatory compliance |
| BLA |
Biologics License Application; the regulatory submission to FDA for marketing approval of a biologic product |
| BTD |
Breakthrough Therapy Designation; an FDA expedited program for drugs intended to treat serious conditions where preliminary evidence shows substantial improvement over existing therapies |
| CAPA |
Corrective and Preventive Action; a systematic process for identifying, investigating, and resolving quality issues to prevent recurrence |
| CBER |
Center for Biologics Evaluation and Research; the FDA center responsible for regulating biological products |
| CDASH |
Clinical Data Acquisition Standards Harmonization; a CDISC standard defining recommended fields for CRF design |
| CDER |
Center for Drug Evaluation and Research; the FDA center responsible for regulating drugs |
| CDISC |
Clinical Data Interchange Standards Consortium; the organization that develops data standards (SDTM, ADaM, CDASH) used in regulatory submissions |
| CEC |
Clinical Events Committee; an independent committee that adjudicates clinical endpoints to ensure consistent classification across sites |
| CFR |
Code of Federal Regulations; the codification of US federal rules, including 21 CFR governing FDA-regulated activities |
| CHMP |
Committee for Medicinal Products for Human Use; the EMA committee responsible for scientific assessment of marketing authorization applications through the centralized procedure |
| CIOMS |
Council for International Organizations of Medical Sciences; an international organization that develops guidelines for safety reporting, including the CIOMS form for individual case safety reports |
| CMC |
Chemistry, Manufacturing, and Controls; the body of data covering a drug product’s composition, manufacturing process, and quality specifications (CTD Module 3) |
| COU |
Context of Use; the specific role and scope for which a drug development tool or AI model is applied |
| CRA |
Clinical Research Associate; a monitor who conducts on-site and remote oversight of investigator sites on behalf of the sponsor |
| CRF |
Case Report Form; the document (paper or electronic) used to record trial data for each participant |
| CRL |
Complete Response Letter; an FDA communication indicating that an application cannot be approved in its current form and specifying deficiencies to address |
| CRO |
Contract Research Organization; a company hired by a sponsor to perform one or more trial-related functions such as monitoring, data management, or regulatory submissions |
| CSR |
Clinical Study Report; the comprehensive document describing the design, conduct, results, and interpretation of a completed clinical trial |
| CSV |
Computer System Validation; the documented process of ensuring that a computerized system performs as intended for its regulated purpose |
| CTA |
Clinical Trial Authorization; the regulatory approval required in certain jurisdictions (e.g., EU) before a clinical trial may begin |
| CTD |
Common Technical Document; the internationally harmonized format for organizing regulatory submissions into five modules |
| CTIS |
Clinical Trials Information System; the EU portal for submitting and managing clinical trial applications under the Clinical Trials Regulation |
| CTMS |
Clinical Trial Management System; software used to manage the operational aspects of clinical trials, including site management, visit tracking, and milestone reporting |
| CTR |
Clinical Trials Regulation; the EU regulation (536/2014) governing clinical trial conduct in member states |
| DCT |
Decentralized Clinical Trial; a trial design where some or all activities occur at locations other than a traditional clinical site, such as the participant’s home |
| DDT |
Drug Development Tool; a method, material, or measure that FDA has qualified to facilitate drug development |
| DHT |
Digital Health Technology; electronic systems that capture health-related data from participants, including wearable sensors, mobile apps, and remote monitoring devices |
| DLT |
Dose-Limiting Toxicity; a pre-defined adverse event in dose-escalation studies that signals the dose has reached an unacceptable level of toxicity |
| DMC |
Data Monitoring Committee; see DSMB |
| DMP |
Data Management Plan; the document specifying procedures for data collection, cleaning, coding, transfer, and quality control throughout a trial |
| DSMB |
Data Safety Monitoring Board; an independent group of experts who periodically review unblinded safety and efficacy data and may recommend stopping or modifying a trial |
| DSUR |
Development Safety Update Report; an annual safety report submitted to regulators summarizing the safety profile of an investigational product across all ongoing trials |
| eCOA |
Electronic Clinical Outcome Assessment; electronic systems for capturing patient-reported, clinician-reported, or observer-reported outcomes |
| eConsent |
Electronic Informed Consent; the use of electronic systems (multimedia, interactive tools) to present and document the informed consent process |
| eCRF |
Electronic Case Report Form; the electronic version of a CRF used within an EDC system to capture trial data |
| eCTD |
Electronic Common Technical Document; the electronic format for submitting the CTD to regulatory agencies |
| EDC |
Electronic Data Capture; a computerized system for collecting clinical trial data in electronic format, replacing paper CRFs |
| EHR |
Electronic Health Record; a digital version of a patient’s medical record maintained by healthcare providers |
| EMA |
European Medicines Agency; the EU regulatory authority responsible for evaluating and supervising medicinal products |
| ePRO |
Electronic Patient-Reported Outcome; patient-reported outcome data collected via electronic devices such as smartphones, tablets, or web portals |
| eTMF |
Electronic Trial Master File; an electronic system for storing and managing essential trial documents required by GCP |
| FDA |
Food and Drug Administration; the US regulatory agency responsible for protecting public health through oversight of drugs, biologics, and medical devices |
| FDORA |
Food and Drug Administration Omnibus Reform Act; 2022 US legislation that modernized FDA authorities, including provisions for decentralized trials and diversity action plans |
| FIH |
First-in-Human; the initial clinical study in which an investigational product is administered to human subjects |
| GAMP |
Good Automated Manufacturing Practice; a framework (GAMP 5) providing guidance on computer system validation in regulated industries |
| GCP |
Good Clinical Practice; the international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials (ICH E6) |
| GDPR |
General Data Protection Regulation; the EU regulation governing the processing and protection of personal data |
| GLP |
Good Laboratory Practice; the quality system governing non-clinical laboratory studies intended to support regulatory submissions |
| GMP |
Good Manufacturing Practice; the quality system governing the manufacture of investigational and commercial pharmaceutical products |
| GxP |
Good Practice; a collective term for quality guidelines and regulations (e.g., GCP, GMP, GLP) in the pharmaceutical industry |
| HIPAA |
Health Insurance Portability and Accountability Act; US legislation that establishes standards for protecting patient health information |
| IB |
Investigator’s Brochure; the document providing investigators with clinical and non-clinical data on the investigational product relevant to the study |
| ICF |
Informed Consent Form; the document that participants sign to confirm they understand and voluntarily agree to participate in a clinical trial |
| ICH |
International Council for Harmonisation; the organization that brings together regulators and industry to develop harmonized guidelines (e.g., E6 GCP, E8, E9) for pharmaceutical development |
| IDMC |
Independent Data Monitoring Committee; see DSMB |
| IEC |
Independent Ethics Committee; a body responsible for reviewing clinical trial protocols to ensure the rights, safety, and well-being of participants are protected; the EU equivalent of an IRB |
| IND |
Investigational New Drug; the FDA application that must be approved before an investigational product can be administered to humans in the US |
| IP |
Investigational Product; the drug, biologic, or device being tested in a clinical trial, including placebo or active comparator |
| IRB |
Institutional Review Board; a committee that reviews and approves clinical research to protect the rights and welfare of human subjects; the US equivalent of an IEC |
| IRT |
Interactive Response Technology; a system that manages randomization and drug supply in clinical trials via web or telephone interfaces |
| ISF |
Investigator Site File; the collection of essential documents maintained at each investigator site for regulatory inspection readiness |
| ITT |
Intent-to-Treat; an analysis population that includes all randomized subjects regardless of protocol adherence |
| IWRS |
Interactive Web Response System; a web-based system for managing randomization and trial supply; a specific type of IRT |
| J-NDA |
Japanese New Drug Application; the regulatory submission to PMDA for marketing approval of a new drug in Japan |
| KRI |
Key Risk Indicator; a metric used in risk-based quality management to monitor trial conduct and trigger risk mitigation actions |
| LLM |
Large Language Model; a type of AI model trained on large text corpora that can generate, summarize, and analyze text |
| LOA |
Likelihood of Approval; a metric estimating the probability that a drug in development will ultimately receive regulatory approval |
| LPLV |
Last Patient Last Visit; the final protocol-specified visit by the last enrolled participant, marking the end of data collection |
| MAA |
Marketing Authorization Application; the regulatory submission to EMA for marketing approval of a medicinal product in the EU |
| MCID |
Minimum Clinically Important Difference; the smallest change in an outcome that patients or clinicians would consider meaningful |
| MCP |
Model Context Protocol; a standard for connecting AI applications to external data sources and tools in a controlled, auditable manner |
| MedDRA |
Medical Dictionary for Regulatory Activities; the standardized medical terminology used for coding adverse events and medical history in clinical trials and pharmacovigilance |
| ML |
Machine Learning; a subset of AI in which algorithms learn patterns from data without being explicitly programmed for each task |
| MTD |
Maximum Tolerated Dose; the highest dose of an investigational product that can be administered without unacceptable toxicity |
| NDA |
New Drug Application; the regulatory submission to FDA for marketing approval of a new drug product |
| NLP |
Natural Language Processing; AI techniques for understanding, interpreting, and generating human language |
| NMPA |
National Medical Products Administration; the regulatory authority in China responsible for drug, device, and cosmetic oversight |
| NOAEL |
No Observed Adverse Effect Level; the highest dose in preclinical studies at which no adverse effects are observed; used to calculate the starting dose for first-in-human trials |
| PD |
Pharmacodynamics; the study of what a drug does to the body, including its mechanism of action and biological effects |
| PDUFA |
Prescription Drug User Fee Act; US legislation authorizing FDA to collect fees from drug manufacturers to fund the drug review process |
| PI |
Principal Investigator; the physician or qualified individual at a trial site who is responsible for the conduct of the trial at that site |
| PK |
Pharmacokinetics; the study of how the body absorbs, distributes, metabolizes, and excretes a drug |
| PMC |
Post-Marketing Commitment; a study or clinical trial that a sponsor agrees to conduct after approval, not required by statute or regulation |
| PMDA |
Pharmaceuticals and Medical Devices Agency; the Japanese regulatory authority responsible for evaluating and approving drugs and medical devices |
| PMR |
Post-Marketing Requirement; a study or clinical trial that a sponsor is required by statute or regulation to conduct after approval |
| PRO |
Patient-Reported Outcome; a measurement of any aspect of a patient’s health status that comes directly from the patient, without interpretation by a clinician |
| QA |
Quality Assurance; the overarching system of planned activities to ensure that trial processes comply with GCP and applicable regulations |
| QC |
Quality Control; the operational techniques and activities undertaken to verify that data and processes meet quality requirements |
| QMS |
Quality Management System; the organizational structure, processes, and resources for implementing quality management across trial activities |
| RAG |
Retrieval-Augmented Generation; an AI technique that grounds language model outputs by retrieving relevant documents before generating a response |
| RBQM |
Risk-Based Quality Management; a systematic approach to trial quality that focuses oversight on the risks most likely to affect participant safety and data reliability (ICH E6 R2/R3) |
| RDEP |
Rare Disease Evidence Principles; regulatory principles guiding the use of innovative evidence approaches in rare disease drug development |
| REMS |
Risk Evaluation and Mitigation Strategy; an FDA-required safety plan for certain drugs with known or potential serious risks, designed to ensure benefits outweigh risks |
| RP2D |
Recommended Phase 2 Dose; the dose selected from Phase I studies for further evaluation in Phase II efficacy trials |
| RTF |
Refuse to File; an FDA decision that a submitted application is insufficiently complete to permit substantive review |
| RTSM |
Randomization and Trial Supply Management; a system that integrates randomization with drug supply logistics, ensuring correct treatment allocation and supply forecasting |
| RWD |
Real-World Data; data relating to patient health status or healthcare delivery collected outside of traditional clinical trials (e.g., from EHRs, claims, registries) |
| RWE |
Real-World Evidence; clinical evidence derived from analysis of real-world data |
| SAE |
Serious Adverse Event; an adverse event that results in death, is life-threatening, requires hospitalization, causes persistent disability, or is a congenital anomaly |
| SAP |
Statistical Analysis Plan; the document specifying the statistical methods, populations, endpoints, and handling of missing data for a clinical trial, finalized before unblinding |
| SDV |
Source Data Verification; the process of comparing data entered in the CRF/EDC against original source documents to ensure accuracy |
| SDTM |
Study Data Tabulation Model; a CDISC standard for organizing and formatting clinical trial data for regulatory submission |
| SIV |
Site Initiation Visit; the visit conducted by the sponsor or CRO to a trial site before enrollment begins, to train staff, review the protocol, and verify site readiness |
| SOP |
Standard Operating Procedure; a documented set of step-by-step instructions for carrying out routine operations in compliance with regulations and quality standards |
| SUSAR |
Suspected Unexpected Serious Adverse Reaction; a serious adverse event that is both suspected to be related to the investigational product and not consistent with known risk information; requires expedited reporting to regulators |
| TLF |
Tables, Listings, and Figures; the standard set of statistical outputs generated from clinical trial data for inclusion in the CSR and regulatory submission |
| TMF |
Trial Master File; the collection of essential documents that individually and collectively permit evaluation of the conduct of a trial and the quality of data produced (ICH E6) |
| VVUQ |
Verification, Validation, and Uncertainty Quantification; the framework for assessing whether computational models are correctly implemented and fit for their intended use |
| WMA |
World Medical Association; the international organization that authored the Declaration of Helsinki, establishing ethical principles for medical research involving human subjects |